Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9339 |
Stafia-1
|
STAT | JAK/STAT signaling; Stem Cells |
Stafia-1 是STAT5a 抑制剂,Ki 为 10.9 μM,IC50 为 22.2 μM。它与 STAT5b 和其他 STAT 家族成员相比,显示出高选择性。 | |||
T82261 | Grb2 SH2 domain inhibitor 1 | ||
Grb2 SH2 domain inhibitor 1是构象受限环细胞穿透肽(CPP),主要用作环状肽基抑制剂,包含特定d-Pro-l-Pro基序环(AFΦrpPRRFQ),其中Φ为l-萘基丙氨酸,r为d-精氨酸,p为d-脯氨酸。 | |||
T77994 |
Grb2 SH2 domain inhibitor 1 TFA
|
||
Grb2 SH2 domain inhibitor 1 TFA 是构象受限的环细胞穿透肽(CPP),含有d-Pro-l-Pro基序环(AFΦrpPRRFQ),Φ为l-萘基丙氨酸,r为d-精氨酸,p为d-脯氨酸,主要用作环状肽基抑制剂。 | |||
T6308 |
Stattic
STAT3 Inhibitor V |
Apoptosis; STAT | Apoptosis; JAK/STAT signaling; Stem Cells |
Stattic (STAT3 Inhibitor V) 是一种 STAT3 抑制剂 (IC50=5.1 μM),选择性地抑制 STAT3 活化、二聚化和核转位。Stattic 具有抗肿瘤活性,可诱导细胞凋亡。 | |||
T9723 |
GluR6 antagonist-1
|
Src | Angiogenesis; Tyrosine Kinase/Adaptors |
GluR6 antagonist-1 抑制酪氨酸激酶 p56lck SH2 结构域的 pY 结合位点。 | |||
T10877 |
CPDA
|
Phosphatase | Metabolism |
CPDA 是新型 SH2 domain-containing inositol phosphatase 2 抑制剂,能够作用于3T3-L1脂肪细胞,改善胰岛素抗性。 | |||
T4216 |
STAT5-IN-1
STAT5 Inhibitor |
STAT | JAK/STAT signaling; Stem Cells |
STAT5-IN-1 (STAT5 Inhibitor) 是STAT5的抑制剂,对 STAT5β 亚型的IC50值为 47 μM。 | |||
T14037 |
3α-Aminocholestane
5α-Cholestan-3α-amine |
Phosphatase | Metabolism |
3α-Aminocholestane (5α-Cholestan-3α-amine) 是包含 SH2 结构域的肌醇-5'-磷酸酶 1 (SHIP1) 的有效抑制剂(IC50 : 2.5 μM),可用于研究和免疫相关的疾病。 | |||
T62491 |
STAT3-IN-13
|
STAT | JAK/STAT signaling; Stem Cells |
STAT3-IN-13 是一种有效的 STAT3 抑制剂。STAT3-IN-13 具有抗增殖和抗癌活性,通过与 STAT3 SH2 结构域结合发挥作用。STAT3-IN-13 抑制 STAT3 Y705 的磷酸化,诱导细胞凋亡 ,抑制肿瘤细胞的生长和转移。STAT3-IN-13 可用于研究乳腺癌和肝癌。 | |||
TQ0003L1 |
740 Y-P acetate
PDGFR 740Y-P Acetate,740YPDGFR acetate,740 Y-P acetate(1236188-16-1 Free base) |
PI3K | PI3K/Akt/mTOR signaling |
740 Y-P acetate (740YPDGFR acetate) 是一个有效的且具有细胞渗透性的 PI3K 激活剂。740 Y-P acetate 倾向和含有 p85 的 N- 和 C- 末端 SH2 结构域的 GST 融合蛋白结合,但不能单独结合 GST。 | |||
T14327 |
AS1949490
|
Phosphatase | Metabolism |
AS1949490 是选择性SHIP-2抑制剂,其IC50=620 nM。它能够通过上调L6肌管GLUT1基因激活葡萄糖代谢。 | |||
TQ0003 |
740 Y-P
740YPDGFR,PDGFR 740Y-P |
PI3K; Autophagy | Autophagy; PI3K/Akt/mTOR signaling |
740 Y-P (740YPDGFR) 是一个细胞渗透性PI3K 激活剂。它能结合含有 p85 的 N- 和 C- 末端 SH2 结构域的 GST 融合蛋白。 | |||
T23751 |
AQX-MN115
|
||
AQX-MN115 is an SH2- containing inositol 5- phosphatase modulator. | |||
T30089 |
AP-22161
AP22161,G7VE62573J,UNII-G7VE62573J,SCHEMBL7243003,AP 22161 |
||
AP-22161 selectively binds the Src SH2 domain by targeting highly conserved phosphotyrosine binding to cysteine residues in the pocket. AP-22161 selectively inhibits Src SH2 binding and can be used to inhibit osteoclast absorption. | |||
T38965 |
EPQpYEEIPIYL
|
||
EPQpYEEIPIYL, a phosphopeptide, is a ligand for the Src homology 2 (SH2) domain. It activates members of the Src family, such as Lck, Hck, and Fyn, through the binding interaction with SH2 domains. | |||
T40219 |
CGP78850
|
||
CGP78850 is a potent and selective Grb2 SH2-phosphopeptide interaction antagonist that holds potential for cancer research. | |||
TP2084 |
N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide
|
||
Phosphopeptide; binds to the src SH2 domain. | |||
T75841 |
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA
|
||
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA(化合物1)是一种与srcSH2域具有高亲和性的五肽,IC50约为1 µM。它同样作为srcSH3-SH2:磷酸蛋白相互作用的抑制剂。 | |||
T27707 |
K118
K 118,K-118 |
||
K118 is an inhibitor of SH2-containing inositol 5' phosphatase 1 (SHIP1). It reverses diet- and age-associated obesity and metabolic syndrome. | |||
T21501 | 5,15-DPP | ||
5,15-Diphenylporphyrin (5,15-DPP) 是一种选择性STAT3-SH2拮抗剂,其对于STAT3 和 STAT1 的IC50值分别为 0.28 μM 和 10 μM。 | |||
TP2085 |
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH
N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu |
||
Phosphopeptide ligand for the src SH2 domain (IC50 = 1 μM). Blocks src interactions with EGFR and FAK. | |||
T24838 |
Stafib-1
Stafib 1,Stafib1 |
STAT | JAK/STAT signaling; Stem Cells |
Stafib-1 是一种特异性的 STAT5β 抑制剂,靶向 SH2 结构域,IC50 为 154 nM,Ki 为 44 nM。 | |||
T75723 |
740 Y-P TFA
|
||
740 Y-P TFA (740YPDGFR;PDGFR740Y-P) 是一个有效的,具有细胞渗透性的PI3K 激活剂。740 Y-P TFA 很容易结合含有 p85 的 N- 和 C- 末端 SH2 结构域的 GST 融合蛋白,但不能单独结合 GST。 | |||
T12905 | SI-109 | STAT | JAK/STAT signaling; Stem Cells |
SI-109 is a potent inhibitor of STAT3 SH2 domain (Ki=9 nM),and with antitumor activity. | |||
T79186 | STAT6-IN-3 | STAT | JAK/STAT signaling; Stem Cells |
STAT6-IN-3 (Compound 18a),一种针对STAT6的Src同源2 (SH2) 结构域的抑制剂,具有44 nM的IC50值。该化合物主要适用于研究哮喘等炎症性疾病。 | |||
T75929 |
Caffeic acid-pYEEIE TFA
|
||
Caffeic acid-pYEEIE TFA 是一种非磷酸肽抑制剂,对 GST-Lck-SH2 结构域具有强大的结合亲和力。 | |||
T74646 | PM-81I | ||
PM-81I为一种高效STAT6抑制剂(针对SH2结构域),可显著减少STAT6的磷酸化水平。适用于研究过敏性肺病、过敏性鼻炎、慢性阻塞性肺病或癌症。 | |||
T26936 |
C188
Cpd188,STAT3-IN-C188,Cpd-188,C 188,C-188 |
||
C188 is a cell-permeable naphthol compound and a STAT3 inhibitor. C188 inhibits IL-6-stimulated STAT3 Tyr705 phosphorylation and nuclear translocation in HepG2 cells by targeting STAT3 SH2 domain peptide-binding pocket, while exhibiting little effect agai | |||
T62724 | AQX-435 | ||
AQX-435 是一种有效的 SHIP1 (SH2 domain-containing inositol-5′-phosphatase 1) 激活剂。AQX-435 能够降低 B 细胞受体 (BCR) 下游 PI3K 活性,诱导恶性 B 细胞凋亡,对淋巴瘤生长表现出抑制作用。 | |||
T60765 |
STAT3-IN-10
|
||
STAT3-IN-10 (A11) 是一种STAT3抑制剂,可直接结合 STAT3 SH2 结构域,抑制肿瘤细胞生长并且诱导肿瘤细胞凋亡 (IC 50 = 5.18 μM)。 | |||
TP2137 |
pp60 c-src (521-533) (phosphorylated)
|
||
Peptide corresponding to the pp60c-src carboxy terminal regulatory domain; phosphorylated at Tyr527. Binds to pp60c-src and pp60v-src at the SH2 domain, suppressing their tyrosine kinase activity and transforming potential. | |||
TP2053 |
Caffeic acid-pYEEIE
|
||
Phosphopeptide ligand for the src SH2 domain (IC50 = 42 nM); displays 30-fold higher affinity than N-acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu (Ac-pYEEIE,). | |||
T73129 |
STAT6-IN-1
|
||
STAT6-IN-1(化合物19a)是一种针对STAT6的SH2结构域表现出较高亲和力(IC50=0.028 µM)的STAT6抑制剂。该化合物主要用于研究过敏性肺病、过敏性鼻炎、慢性阻塞性肺病或癌症。 | |||
T35429 |
AC-4-130
|
||
AC-4-130, a powerful inhibitor of the SH2 domain of STAT5, effectively hinders STAT5 activation, dimerization, nuclear translocation, and transcription of genes reliant on STAT5. This compound directly binds to STAT5, ultimately leading to cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 exhibits notable anti-cancer properties and effectively suppresses abnormal STAT5 activity in acute myeloid leukemia (AML), making it a promising therapeutic option [1]. | |||
T79662 | STAT3-IN-20 | STAT | JAK/STAT signaling; Stem Cells |
STAT3-IN-20(Compound 40)是一种选择性地靶向STAT3的SH2结构域,展现了在DU145和MDA-MB-231癌细胞中的抗增殖效果(IC50分别为2.97 μM和3.26 μM),并诱导细胞周期停滞与细胞凋亡。该抑制剂有效抑制了STAT3的磷酸化、核内易位及其下游基因的转录活性(IC50: 0.65 μM)。 |